Recessive cancer genes engage in negative genetic interactions with their functional paralogs

Cell Reports

Volumn 5, Issue 6, 2013, Pages 1519-1526

  D'Antonio, Matteo ^a   Guerra, Rosalinda F ^a   Cereda, Matteo ^a   Marchesi, Stefano ^a   Montani, Francesca ^a   Nicassio, Francesco ^a,b   DiFiore, PierPaolo ^a,c,d   Ciccarelli, Francesca D ^a,e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE;

ARTICLE; CANCER GENE THERAPY; CARCINOGENESIS; CDH1 GENE; CDH3 GENE; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNMT1 GENE; DNMT3A GENE; DNMT3B GENE; GENE DUPLICATION; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; GENETIC CODE; HUMAN; LOSS OF FUNCTION MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PARALOGY; PRIORITY JOURNAL; RECESSIVE GENE; SMARCA2 GENE; SMARCA4 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE;

CADHERINS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA HELICASES; EPISTASIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENES, RECESSIVE; HUMANS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 84891038218     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.11.033     Document Type: Article

References (34)

1. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J.Clin. Oncol. 2008, 26:3785-3790.
2. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
3. Black A., Morris D. Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr. Oncol. 2012, 19(Suppl 1):S73-S85.
4. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
5. Bultman S.J., Herschkowitz J.I., Godfrey V., Gebuhr T.C., Yaniv M., Perou C.M., Magnuson T. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 2008, 27:460-468.
6. Ciccarelli F.D. The (r)evolution of cancer genetics. BMC Biol. 2010, 8:74.
7. D'Antonio M., Ciccarelli F.D. Modification of gene duplicability during the evolution of protein interaction network. PLoS Comput. Biol. 2011, 7:e1002029.
8. Dong Y., Li A., Wang J., Weber J.D., Michel L.S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70:5465-5474.
9. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
10. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39(Database issue):D945-D950.
11. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
12. Hulpiau P., van Roy F. Molecular evolution of the cadherin superfamily. Int. J. Biochem. Cell Biol. 2009, 41:349-369.
13. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10:805-811.
14. Kent W.J. BLAT-the BLAST-like alignment tool. Genome Res. 2002, 12:656-664.
15. Kothandapani A., Gopalakrishnan K., Kahali B., Reisman D., Patrick S.M. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. Exp. Cell Res. 2012, 318:1973-1986.
16. Letunic I., Doerks T., Bork P. SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res. 2012, 40(Database issue):D302-D305.
17. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., Kandoth C., Payton J.E., Baty J., Welch J., et al. DNMT3A mutations in acute myeloid leukemia. N.Engl. J. Med. 2010, 363:2424-2433.
18. Mastracci T.L., Tjan S., Bane A.L., O'Malley F.P., Andrulis I.L. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma insitu of the breast. Mod. Pathol. 2005, 18:741-751.
19. Pawlak M., Jaenisch R. De novo DNA methylation by Dnmt3a and Dnmt3b is dispensable for nuclear reprogramming of somatic cells to a pluripotent state. Genes Dev. 2011, 25:1035-1040.
20. Pruefer F.G., Lizarraga F., Maldonado V., Melendez-Zajgla J. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J.Chemother. 2008, 20:348-354.
21. Pruitt K.D., Tatusova T., Klimke W., Maglott D.R. NCBI Reference Sequences: current status, policy and new initiatives. Nucleic Acids Res. 2009, 37(Database issue):D32-D36.
22. Rambaldi D., Giorgi F.M., Capuani F., Ciliberto A., Ciccarelli F.D. Low duplicability and network fragility of cancer genes. Trends Genet. 2008, 24:427-430.
23. Reisman D.N., Sciarrotta J., Wang W., Funkhouser W.K., Weissman B.E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003, 63:560-566.
24. Reisman D., Glaros S., Thompson E.A. The SWI/SNF complex and cancer. Oncogene 2009, 28:1653-1668.
25. Renneville A., Boissel N., Nibourel O., Berthon C., Helevaut N., Gardin C., Cayuela J.M., Hayette S., Reman O., Contentin N., et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012, 26:1247-1254.
26. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 2004, 22:326-330.
27. Rodriguez-Nieto S., Cañada A., Pros E., Pinto A.I., Torres-Lanzas J., Lopez-Rios F., Sanchez-Verde L., Pisano D.G., Sanchez-Cespedes M. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum. Mutat. 2011, 32:E1999-E2017.
28. Saito M., Tucker D.K., Kohlhorst D., Niessen C.M., Kowalczyk A.P. Classical and desmosomal cadherins at a glance. J.Cell Sci. 2012, 125:2547-2552.
29. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
30. VanderSluis B., Bellay J., Musso G., Costanzo M., Papp B., Vizeacoumar F.J., Baryshnikova A., Andrews B., Boone C., Myers C.L. Genetic interactions reveal the evolutionary trajectories of duplicate genes. Mol. Syst. Biol. 2010, 6:429.
31. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
32. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
33. Willis M.S., Homeister J.W., Rosson G.B., Annayev Y., Holley D., Holly S.P., Madden V.J., Godfrey V., Parise L.V., Bultman S.J. Functional redundancy of SWI/SNF catalytic subunits in maintaining vascular endothelial cells in the adult heart. Circ. Res. 2012, 111:e111-e122.
34. Zhang C.C., Yan Z., Zhang Q., Kuszpit K., Zasadny K., Qiu M., Painter C.L., Wong A., Kraynov E., Arango M.E., et al. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin. Cancer Res. 2010, 16:5177-5188.